Ernexa Therapeutics Inc. (ERNA) Stock Price & Analysis

Ernexa Therapeutics Inc. (ERNA) fell 7.98% to USD 6.8 as of June 10, 2026 at 12:15 UTC, according to Nexqual real-time market data.

ERNA last closed at USD 7.39; the session ranged USD 6.8–7.84 on volume of 56,907 shares. Market capitalization is $7.93M, with a 52-week range of USD 3.18–71.5 (NCM). Source: Nexqual, June 10, 2026 at 12:15 UTC.

Key Statistics (as of June 10, 2026 at 12:15 UTC)

Technical Analysis (ERNA)

Nexqual's technical model rates ERNA "NEUTRAL" based on 3 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 12:15 UTC.

Analyst Ratings (ERNA)

Wall Street analysts rate ERNA "Strong Buy" based on 1 analysts, with a mean price target of USD 30 (range USD 30–30), per Nexqual as of June 10, 2026 at 12:15 UTC.

Earnings (ERNA)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 12:15 UTC.

Financials & Fundamentals (ERNA)

Source: Nexqual, June 10, 2026 at 12:15 UTC.

Financial Health Score (ERNA)

Nexqual rates Ernexa Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:15 UTC.

Ownership (ERNA)

Source: Nexqual, June 10, 2026 at 12:15 UTC.

Leadership (ERNA)

Ernexa Therapeutics Inc. is led by Sanjeev Luther (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 12:15 UTC.

Major Backers & Investors (ERNA)

Notable institutional backers of Ernexa Therapeutics Inc. include Fidelity, Bleichroeder LP, Dauntless Investment Group, LLC , according to Nexqual as of June 10, 2026 at 12:15 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 12:15 UTC.

From Ernexa Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)

Key Strengths & Strategy (as disclosed to the SEC)

• The legal systems of certain countries, particularly certain developing countries including India and China, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our in-licensed patents or marketing of competing products in violation of our proprietary rights generally.
• The FDA typically conducts a review of proposed proprietary product names, including an evaluation of potential for confusion with other product names.
• If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA.
• Although we seek such protection in part by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:15 UTC. This page is informational and not investment advice.